The Saudi consensus recommendations for the management of psoriatic arthritis (2023)
AbstractPsoriatic arthritis (PsA) is a complex inflammatory disease characterized by musculoskeletal and non-musculoskeletal manifestations. It is a distinct disease entity at the interface between rheumatology and dermatology, making it challenging to manage. The diverse clinical presentation and severity of PsA require a multidisciplinary approach for optimal care. Early diagnosis and management are necessary to improving quality of life for patients. In Saudi Arabia, there is currently no unified national consensus on the best practices for managing PsA. This lack of consensus leads to debate and uncertainty in the trea...
Source: Clinical Rheumatology - January 13, 2024 Category: Rheumatology Source Type: research
Content analysis of patient support groups related to myositis on Facebook
ConclusionsOur observations indicate that patients with myositis seek information on the condition online, and the multimedia nature of content presentation significantly influences engagement. These digital forums serve as valuable platforms for fostering connections among diverse individuals, providing a perceived safe space for sharing their personal experiences and varied perspectives, and potentially mitigating social isolation.Key Points•Patient support groups on myositis are a key source of support and information for patients.•Public posts with multimedia content garner the most engagement.•The majority of po...
Source: Clinical Rheumatology - January 12, 2024 Category: Rheumatology Source Type: research
Umbilical cord mesenchymal stem cells transplantation in patients with systemic sclerosis: a 5-year follow-up study
ConclusionUMSCT may provide a safe and feasible treatment option for patients with moderate to severe SSc based on long-term follow-up data. The randomized controlled study will further confirm the clinical efficacy of UMSCT in SSc.Clinical Trial RegistrationClinicalTrials.gov Identifier: NCT00962923.Key Point•UMSCT is safe and effective for SSc patients. (Source: Clinical Rheumatology)
Source: Clinical Rheumatology - January 11, 2024 Category: Rheumatology Source Type: research
Sex-specific differences in patients with psoriatic arthritis:a nationwide study from the Chinese Registry of Psoriatic Arthritis (CREPAR IV)
ConclusionDemographic and clinical characteristics tend to vary between male and female patients with PsA. Male patients reported more functional limitations in daily life.Key Points•The demographic and clinical features vary greatly between male and female patients with PsA.•Male patients reported more functional burden in daily life as measured by BASFI. (Source: Clinical Rheumatology)
Source: Clinical Rheumatology - January 10, 2024 Category: Rheumatology Source Type: research
Cumulative pulse methylprednisolone and its relation to disease activity, damage and mortality in systemic lupus erythematosus patients: A post hoc analysis of COMOSLE-EGYPT study
ConclusionWith every gram increase in the cumulative methylprednisolone, there may be increase in damage and mortality, especially in doses exceeding the range of 2.75 –3.25 g.Key Points• Treatment of systemic lupus erythematosus should be with the least possible dose of steroids to decrease the risk of damage and mortality.• With every gram increase in the cumulative intravenous methylprednisolone there may be increase in damage and mortality. (Source: Clinical Rheumatology)
Source: Clinical Rheumatology - January 10, 2024 Category: Rheumatology Source Type: research
Sex-specific differences in patients with psoriatic arthritis:a nationwide study from the Chinese Registry of Psoriatic Arthritis (CREPAR IV)
ConclusionDemographic and clinical characteristics tend to vary between male and female patients with PsA. Male patients reported more functional limitations in daily life.Key Points•The demographic and clinical features vary greatly between male and female patients with PsA.•Male patients reported more functional burden in daily life as measured by BASFI. (Source: Clinical Rheumatology)
Source: Clinical Rheumatology - January 10, 2024 Category: Rheumatology Source Type: research
Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study
ConclusionsOur results do not provide evidence to support the hypothesis that reducing LDL-C levels with statins, alirocumab, or ezetimibe effectively prevents the risk of developing RA. However, our study provides valuable insights into the assessment of lipid-lowering agents in RA, which can enhance our understanding of the condition and assist in clinical practice by aiding in the determination and monitoring of RA status to clinical response.Key Points• Common lipid-lowering drugs such as statins, alirocumab, or evolocumab may not effectively prevent the development of rheumatoid arthritis.• This study provides clu...
Source: Clinical Rheumatology - January 10, 2024 Category: Rheumatology Source Type: research
Cumulative pulse methylprednisolone and its relation to disease activity, damage and mortality in systemic lupus erythematosus patients: A post hoc analysis of COMOSLE-EGYPT study
ConclusionWith every gram increase in the cumulative methylprednisolone, there may be increase in damage and mortality, especially in doses exceeding the range of 2.75 –3.25 g.Key Points• Treatment of systemic lupus erythematosus should be with the least possible dose of steroids to decrease the risk of damage and mortality.• With every gram increase in the cumulative intravenous methylprednisolone there may be increase in damage and mortality. (Source: Clinical Rheumatology)
Source: Clinical Rheumatology - January 10, 2024 Category: Rheumatology Source Type: research
Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study
ConclusionsOur results do not provide evidence to support the hypothesis that reducing LDL-C levels with statins, alirocumab, or ezetimibe effectively prevents the risk of developing RA. However, our study provides valuable insights into the assessment of lipid-lowering agents in RA, which can enhance our understanding of the condition and assist in clinical practice by aiding in the determination and monitoring of RA status to clinical response.Key Points• Common lipid-lowering drugs such as statins, alirocumab, or evolocumab may not effectively prevent the development of rheumatoid arthritis.• This study provides clu...
Source: Clinical Rheumatology - January 10, 2024 Category: Rheumatology Source Type: research
Microvascular status in juvenile Sj ögren’s disease: the first nailfold videocapillaroscopy investigation
ConclusionsThe reduction of capillary density, as well as microhaemorrhages at NVC analysis, are significantly associated with some clinical aspects like articular involvement and serum biomarkers (C3 reduction). The NVC is suggested as safe and further analysis in jSjD patients.Key Points• Juvenile Sjögren’s disease (jSjD) exhibits a higher rate of abnormal shapes at nailfold videocapillaroscopy (NVC) compared to matched healthy controls.• Articular involvement in jSjD is significantly associated with a lower capillary number at NVC.• Microhaemorrhages on NVC are associated with lower C3 levels, prompting this fi...
Source: Clinical Rheumatology - January 8, 2024 Category: Rheumatology Source Type: research
